Sami Ibrahimi

2.4k total citations · 1 hit paper
33 papers, 387 citations indexed

About

Sami Ibrahimi is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Sami Ibrahimi has authored 33 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 8 papers in Genetics. Recurrent topics in Sami Ibrahimi's work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sami Ibrahimi is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sami Ibrahimi collaborates with scholars based in United States, Japan and Netherlands. Sami Ibrahimi's co-authors include Alessandro Previtali, Jon Arnason, Pim Mutsaers, Koji Izutsu, Mohamad Cherry, Alessandro Crotta, Bertram Glaß, Scott R. Solomon, Sandrine Montheard and Jeremy S. Abramson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sami Ibrahimi

29 papers receiving 384 citations

Hit Papers

Lisocabtagene maraleucel as second-line therapy for large... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
    2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sami Ibrahimi United States 9 277 158 66 61 59 33 387
Pim Mutsaers Netherlands 8 270 1.0× 185 1.2× 41 0.6× 59 1.0× 39 0.7× 30 371
Alessandro Crotta United States 7 273 1.0× 121 0.8× 50 0.8× 55 0.9× 28 0.5× 26 369
Brian Elliott United States 11 359 1.3× 261 1.7× 95 1.4× 88 1.4× 24 0.4× 32 482
Vincent Camus France 12 207 0.7× 319 2.0× 89 1.3× 32 0.5× 76 1.3× 48 527
Houston Holmes United States 12 319 1.2× 146 0.9× 79 1.2× 119 2.0× 30 0.5× 39 540
Meirav Kedmi Israel 10 129 0.5× 148 0.9× 53 0.8× 35 0.6× 75 1.3× 33 283
Paul Maciocia United Kingdom 9 378 1.4× 121 0.8× 32 0.5× 153 2.5× 22 0.4× 23 504
Uri Abadi Israel 9 141 0.5× 129 0.8× 35 0.5× 49 0.8× 27 0.5× 28 298
Eugenio Galli Italy 9 176 0.6× 43 0.3× 29 0.4× 49 0.8× 15 0.3× 43 280
Jörg Faber Germany 11 192 0.7× 31 0.2× 44 0.7× 106 1.7× 52 0.9× 31 466

Countries citing papers authored by Sami Ibrahimi

Since Specialization
Citations

This map shows the geographic impact of Sami Ibrahimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sami Ibrahimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sami Ibrahimi more than expected).

Fields of papers citing papers by Sami Ibrahimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sami Ibrahimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sami Ibrahimi. The network helps show where Sami Ibrahimi may publish in the future.

Co-authorship network of co-authors of Sami Ibrahimi

This figure shows the co-authorship network connecting the top 25 collaborators of Sami Ibrahimi. A scholar is included among the top collaborators of Sami Ibrahimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sami Ibrahimi. Sami Ibrahimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations
2.
Steiner, Raphaël, Allison M. Bock, Alex F. Herrera, et al.. (2024). CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab. Blood. 144(Supplement 1). 4434.2–4434.2. 1 indexed citations
3.
4.
Adam, Karolina, et al.. (2024). Recombinant ADAMTS13: an effective rescue therapy for acute cTTP during pregnancy. Blood Advances. 8(14). 3718–3720. 9 indexed citations
5.
Andorsky, David, Ralph V. Boccia, Bradley W. Lash, et al.. (2024). Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.. Journal of Clinical Oncology. 42(16_suppl). 7029–7029. 1 indexed citations
6.
Boggio, Lisa, Manuel Carção, Sami Ibrahimi, et al.. (2023). Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. 29(6). 1638–1645. 2 indexed citations
7.
Narkhede, Mayur, Nancy L. Bartlett, Sami Ibrahimi, et al.. (2023). A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL). SHILAP Revista de lepidopterología. 4(2). 370–380. 6 indexed citations
8.
Pandey, Manu, et al.. (2023). Impact of primary organ site of involvement by peripheral T‐cell lymphoma not otherwise specified on survival. Cancer Medicine. 12(24). 21770–21778. 2 indexed citations
9.
10.
Hall, Spencer R., Yan D. Zhao, Manu Pandey, et al.. (2023). Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23(5). 379–384. 3 indexed citations
11.
Abramson, Jeremy S., Patrick B. Johnston, Manali Kamdar, et al.. (2022). Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances. 6(23). 5969–5979. 17 indexed citations
12.
Assi, Hussein, Adam S. Asch, Michael Machiorlatti, Sara K. Vesely, & Sami Ibrahimi. (2020). Development of Thrombocytopenia is Associated with Improved Survival in Patients Treated with Immunotherapy. Future Science OA. 6(7). FSO581–FSO581. 13 indexed citations
13.
Ibrahimi, Sami, et al.. (2020). Primary Mantle Cell Lymphoma of the Tonsil: A Case Series. Blood. 136(Supplement 1). 14–14.
14.
Mukherjee, Sarbajit, et al.. (2018). Degloving the Feet: A Severe Case of Hand-Foot Syndrome After Induction Chemotherapy. Journal of Cutaneous Medicine and Surgery. 22(6). 609–609.
15.
Mukherjee, Sarbajit, et al.. (2018). Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA). Hematology/Oncology and Stem Cell Therapy. 11(3). 187–188. 8 indexed citations
16.
Mukherjee, Sarbajit, et al.. (2018). Granulocytic sarcoma and mediastinal germ cell tumor. Hematology/Oncology and Stem Cell Therapy. 12(4). 228–229. 1 indexed citations
17.
Ibrahimi, Sami. (2018). Effect of time of admission to treatment initiation on outcomes of patients with acute myeloid leukemia: a tertiary care referral center experience. The Journal of Community and Supportive Oncology. 16(5). e188–e193. 4 indexed citations
18.
Ibrahimi, Sami, et al.. (2017). Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience. Blood. 130. 4864–4864. 23 indexed citations
19.
Mukherjee, Sarbajit, et al.. (2017). Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia. Annals of Hematology. 96(9). 1435–1439. 18 indexed citations
20.
Ibrahimi, Sami, et al.. (2017). Extranodal Marginal Zone Lymphoma of the Central Nervous System. Clinical Lymphoma Myeloma & Leukemia. 18(1). 34–37.e8. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pim Mutsaers Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Brian Elliott Breakdown of academic impact, for papers by Vincent Camus Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by Meirav Kedmi Breakdown of academic impact, for papers by Paul Maciocia Breakdown of academic impact, for papers by Uri Abadi Breakdown of academic impact, for papers by Eugenio Galli Breakdown of academic impact, for papers by Jörg Faber
Rankless by CCL
2026